Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities

Obesity is a chronic disease with a rapidly increasing prevalence associated with significant comorbidities. Petrelintide is a long-acting amylin analog in development for weight management. This is a randomized, double-blind, placebo-controlled, parallel-group, multinational, multicenter, dose-finding, Phase 2 clinical trial. The trial will compare 5 doses of once-weekly (OW) subcutaneously administered petrelintide with placebo. This study consists of 3 periods: 1. A screening period of 2-3 weeks 2. A treatment period of 42 weeks 3. A safety follow-up period of 9 weeks.